Natalia Malara, M.D.,Ph.D.,
IRC-FSH "Magna Graecia" University,
Dipartimento di Scienze della Salute- Livello 4,
Universita' Magna Graecia di Catanzaro,
88100 Loc. Germaneto - Catanzaro (Italy).
- circulating tumor cells,
- circulating endothelial cells,
- personalized oncologic therapy,
- early cancer detection
- Natalia Malara is a medical oncologist with competence of translational medicine in human cellular biology, nanotechnology and toxicology with particular interest in Oncologic and cardiovascular field.
- Researcher at IRC-FSH Institute, Department of Health Science of University of Magna Graecia,
Responsible of the projects:
- Circulating Endothelial Cells and exosomes characterization in acute coronary syndrome without S-T elevation ( ENXO-CARDIAL STUDY) 2015
- Circulating Endothelial Cells in the Atrial Fibrillation risk evaluation ( ENDO-FIRE STUDY) 2015rn-Anti-oxidant effects on circulating Breast cancer cells (OXICIRCEM STUDY) 2015
- Characterization of Circulating Tumor cells and Expansion (CHARACTEX STUDY) 2015.
- She was an active researcher collaborator at the Experimental Medicine Department of the University "Magna Graecia" of Catanzaro (UMG), since October 2006 and Senior postdoc at UMG and Italian Institute of Technology (IIT).
Author of the book:
- The Cancer Tissue, published Eurilink and distributed by Feltrinelli. Author of two patents on the systems of cultivation of primary tumor cells. Medical oncologist with expertise in Ultrasound-Color Doppler Oncology (at Agoust 2016, 1352 echography were performed).
- She conducts clinical and laboratory investigations focusing her attention on circulating tumor and endothelial cells. He acquired a solid experience in nano-biotechnology techniques with translational approach in medicine collaborating with Bionem group guided by Prof Di Fabrizio .
- She begin her collaboration with Prof Mollace group in July 2010, and since then his research activities are focused on nanotechnology for biomedical and pharmacological applications on oncologic field in pre-clinical model and clinical trial.